GABA Receptor PAM Combination Therapy for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and inflammatory responses require high doses of GABA due to its low affinity and short half-life, making them cumbersome and reducing patient compliance, while existing therapies for immune modulation are inadequate in reducing inflammatory responses and promoting regulatory immune responses effectively.
Innovation Solution
Administering a GABAA receptor positive allosteric modulator (PAM) in combination with a GABA receptor activating ligand to reduce inflammatory immune responses and promote regulatory immune responses, using lower dosages than traditional therapies, thereby synergistically enhancing beta-cell replication and function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of GABA are administered to achieve therapeutic efficacy, then immune modulation effect is improved, but patient compliance deteriorates due to cumbersome dosing regimen
Solution Approach 1:
The patent changes the pharmacological parameters by introducing PAMs that alter the affinity and duration of action at GABA receptors. This allows achieving therapeutic immune modulation effects with lower doses of GABA or its agonists, transforming the dosing regimen from frequent high-dose administration to more convenient lower-dose administration while maintaining or enhancing efficacy
Solution Approach 2:
The patent creates a composite pharmacological approach by combining GABA (or its agonists) with PAMs. This composite therapy produces synergistic effects where the PAM enhances the binding affinity and duration of GABA receptor activation, allowing reduced GABA dosage while maintaining therapeutic efficacy, thereby improving patient compliance
2Reliability
If multiple grams of GABA are administered several times daily to overcome short half-life, then therapeutic efficacy is maintained, but treatment complexity increases
Solution Approach 1:
The patent modifies the temporal parameters of drug action by using PAMs that prolong the duration of GABA receptor activation. This extends the effective half-life of the therapeutic effect, reducing the frequency of administration needed to maintain therapeutic efficacy and simplifying the treatment regimen
Solution Approach 2:
The PAM acts as a pharmacological intermediary that bridges the gap between short-lived GABA and sustained therapeutic effect. The PAM remains bound to the receptor and facilitates prolonged activation, serving as a mediator that converts brief GABA exposure into extended therapeutic action, thereby reducing dosing frequency and treatment complexity
Data Source
AI summary
Embodiments methods of reducing an inflammatory immune response (e.g., inhibiting a Th1 response) and/or promoting a regulatory immune response (e.g., enhancing Treg(s)) in a mammal are provided where the method methods involve administering to the mammal a GABAA receptor positive allosteric modulator (PAM) in an amount sufficient to reduce an inflammatory immune response and/or to promote a regulatory immune response said mammal. In certain embodiments the PAM is administered in conjunction with a GABA receptor activating ligand (e.g., GABA).